Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models

Theodora M. Steindl,* Daniela Schuster, Christian Laggner, Karen Chuang,§ Rémy D. Hoffmann,# and Thierry Langer*
Institute of Pharmacy, Computer Aided Molecular Design Group, University of Innsbruck, Innrain 52c and Center for Molecular Biosciences Innsbruck (CMBI), Peter-Mair-Strasse 1, A-6020 Innsbruck, Austria, Inte:Ligand GmbH, Clemens Maria Hofbauer-Gasse 6, A-2344 Maria Enzersdorf, Austria, Accelrys Inc., 10188 Telesis Court, Suite 100, San Diego, California 92121, and Accelrys SARL, Parc Club Orsay Universit, 20, rue Jean Rostand, 91898 Orsay, Cedex, France
J. Chem. Inf. Model., 2007, 47 (2), pp 563–571
DOI: 10.1021/ci600321m
Publication Date (Web): January 17, 2007
Copyright © 2007 American Chemical Society
*

 Corresponding author addresses:  Institute of Pharmacy, Department of Pharmaceutical Chemistry, Innrain 52c, University of Innsbruck, A-6020 Innsbruck, Austria (T.L.). Corresponding author phone:  +43 512 507 5252; fax:  +43 512 507 5269; e-mail:  thierry.langer@uibk.ac.at. (T.L.) and e-mail:  theodora.steindl@uibk.ac.at (T.M.S.).

,

 University of Innsbruck and Center for Molecular Biosciences Innsbruck (CMBI).

,

 Inte:Ligand GmbH.

,
§

 Accelrys Inc.

,
#

 Accelrys SARL, Parc Club Orsay Université.

Abstract

Abstract Image

Parallel Screening has been introduced as an in silico method to predict the potential biological activities of compounds by screening them with a multitude of pharmacophore models. This study presents an early application example employing a Pipeline Pilot-based screening platform for automatic large-scale virtual activity profiling. An extensive set of HIV protease inhibitor pharmacophore models was used to screen a selection of active and inactive compounds. Furthermore, we aimed to address the usually critically eyed point, whether it is possible in a parallel screening system to differentiate between similar molecules/molecules acting on closely related proteins, and therefore we incorporated a collection of other protease inhibitors including aspartic protease inhibitors. The results of the screening experiments show a clear trend toward most extensive retrieval of known active ligands, followed by the general protease inhibitors and lowest recovery of inactive compounds.

Tools

Accession Codes

History

  • Published In Issue March 26, 2007
  • Received July 28, 2006

Recommend & Share

Related Content

Other ACS content by these authors: